



ASX Announcement

24 June 2021

Results of Annual General Meeting

Creso Pharma Limited (ASX:CPH) ('Creso Pharma' or 'the Company') held an Annual General Meeting of Shareholders at Quest East Perth, 176 Adelaide Terrace, East Perth WA 6004.

All resolutions were determined by poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in Annexure A.

Ends

Authority and Contact Details

This announcement has been authorised for release by Eryn Dale, Joint Company Secretary.

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Media Enquiries

Ben Jarvis | Six Degrees Group

E: ben.jarvis@sdir.com.au

P: +61 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

ANNEXURE A

Disclosure of Proxy Votes

Creso Pharma Limited

Annual General Meeting

Thursday, 24 June 2021



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	65,016,077	59,521,593 91.55%	3,545,733 5.45%	169,532,416	1,948,751 3.00%	61,477,844 94.55%	3,545,733 5.45%	169,840,093
2 Re-Election of Director – Boaz Wachtel	P	253,040,195	247,518,840 97.82%	2,030,542 0.80%	348,053	3,490,813 1.38%	251,017,153 99.20%	2,030,542 0.80%	655,730
3 Approval of 7.1A Mandate	P	252,174,869	247,434,569 98.12%	2,700,983 1.07%	1,213,379	2,039,317 0.81%	249,481,386 98.93%	2,700,983 1.07%	1,521,056
4 Issue of Shares in Consideration for the Halucenex Acquisition	P	252,959,531	248,733,803 98.33%	2,337,129 0.92%	428,717	1,888,599 0.75%	250,629,902 98.98%	2,587,129 1.02%	486,394
5 Issue of Shares and Performance Shares in Consideration for the Halucenex Acquisition	P	253,183,378	248,224,987 98.04%	3,059,242 1.21%	204,870	1,899,149 0.75%	250,131,636 98.69%	3,309,242 1.31%	262,547
6 Creation of a New Class of Securities – Performance Shares	P	252,903,694	245,749,490 97.17%	3,732,078 1.48%	484,554	3,422,126 1.35%	249,429,116 98.53%	3,732,078 1.47%	542,231
7 Ratification of Prior Issue of Consultant Options	P	253,017,982	246,381,481 97.38%	3,231,189 1.28%	370,266	3,405,312 1.35%	249,794,293 98.63%	3,481,189 1.37%	427,943



Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
8 Ratification of Prior Issue of Shares to Lenders	P	223,069,557	216,650,073 97.12%	3,030,749 1.36%	350,426	3,388,735 1.52%	220,046,308 98.53%	3,280,749 1.47%	408,103
9 Approval to Issue Options to Lenders	P	222,823,145	216,287,621 97.07%	3,176,399 1.43%	596,838	3,359,125 1.51%	219,654,246 98.46%	3,426,399 1.54%	654,515
10 Ratification of Prior Issue of Placement Shares	P	250,750,514	244,352,391 97.45%	3,000,906 1.20%	596,158	3,397,217 1.35%	247,757,108 98.70%	3,250,906 1.30%	653,835
11 Approval to Issue Placement Options	P	250,578,744	244,080,028 97.41%	3,099,399 1.24%	662,225	3,399,317 1.36%	247,486,845 98.66%	3,349,399 1.34%	719,902
12 Approval to issue Broker Shares to Everblu Capital	P	74,321,241	66,721,374 89.77%	4,219,983 5.68%	146,893,919	3,379,884 4.55%	70,108,758 94.01%	4,469,983 5.99%	146,951,596
13 Approval to Issue Options to Everblu Capital	P	74,046,605	66,670,494 90.04%	3,939,087 5.32%	147,168,555	3,437,024 4.64%	70,115,018 94.36%	4,189,087 5.64%	147,226,232
14 Adoption of Incentive Plan	P	65,055,918	57,859,952 88.94%	3,783,009 5.82%	169,492,575	3,412,957 5.25%	61,272,909 93.82%	4,033,009 6.18%	169,550,252
15 Approval to Issue Shares to Related Party – Mr Boaz Wachtel	P	244,486,155	236,639,970 96.79%	4,489,255 1.84%	8,902,093	3,356,930 1.37%	240,004,400 98.06%	4,739,255 1.94%	8,959,770
16 Approval to Issue Shares to Related Party – Dr James Ellingford	P	252,133,655	244,401,336 96.93%	4,335,389 1.72%	1,254,593	3,396,930 1.35%	247,805,766 98.18%	4,585,389 1.82%	1,312,270
17 Issue of Shares to Consultant – Mr Jorge Wernli	P	239,143,425	231,320,595 96.73%	4,402,607 1.84%	14,244,823	3,420,223 1.43%	234,748,318 98.06%	4,652,607 1.94%	14,302,500

